Walaphage G 1 Forte Tablet PR contains a combination of Glimepiride 1mg and Metformin 1000mg, formulated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and improving peripheral insulin sensitivity, enhancing glucose uptake and utilization. This dual-action mechanism provides effective glycemic control in patients inadequately managed by diet, exercise, or monotherapy. The prolonged-release formulation ensures a steady plasma concentration, minimizing peak-related adverse effects and improving patient compliance. Walaphage G 1 Forte is indicated for adult patients with type 2 diabetes who require combination therapy to achieve target glycemic levels. It should be used alongside lifestyle modifications such as diet and exercise. Caution is advised in patients with renal impairment, hepatic dysfunction, or cardiovascular conditions. Common side effects may include gastrointestinal disturbances, hypoglycemia, and rarely, lactic acidosis. Regular monitoring of blood glucose, renal function, and periodic assessment of hematological parameters is recommended during therapy. Walaphage G 1 Forte Tablet PR should be prescribed and administered under medical supervision to ensure optimal therapeutic outcomes and minimize risks.